Metastatic Colorectal Cancer: Applying Evidence-based Recommendations for Evaluation and Management by MCM Education
WebcastFaculty
OVERVIEW
Metastatic Colorectal Cancer: Applying Evidence-based Recommendations for Evaluation and Management is organized by Medical Communications Media (MCM) Education and will be held during Feb 06, 2018 - Feb 06, 2019.
The target audience for this medical event is Medical oncologists, radiation oncologists, surgical oncologists, pathologists, oncology NPs and PAs, oncology nurses and other healthcare providers involved in the treatment of patients with colorectal cancer. This CME Conference has been approved for a maximum of 1.0 AMA PRA Category 1 Credits.
Accrediation :
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.8 contact hours. Designated for 0.4 pharmacotherapy contact hours for Advance Practice Registered Nurses.
Course Description :
Colorectal cancer is the third most common cancer in men and women. Current evidence-based guidelines recommend that all metastatic colorectal tumors be tested for RAS mutations (both KRAS and NRAS) and BRAF mutations, as the presence of such mutations has implications for treatment. Clinical practice is variable, however, and many patients do not receive guideline-based care. This activity will examine optimal management of metastatic colorectal cancer.
Conference Objectives are :
Upon completion of this educational activity, the participant should be able to:
• Discuss the clinical relevance of extended RAS analysis at diagnosis and first relapse, BRAF testing, and MSI testing during workup for mCRC patients.
• Apply the most current evidence-based clinical practice guidelines to the management of patients with mCRC.
• Describe a multidisciplinary team approach to the management of mCRC involving surgery, radiation, and other treatment modalities.
• Review efficacy and safety data from clinical trials of approved agents being investigated for new indications in mCRC and for emerging investigational agents for the management of mCRC.
Additional details will be posted as soon as they are available.
The target audience for this medical event is Medical oncologists, radiation oncologists, surgical oncologists, pathologists, oncology NPs and PAs, oncology nurses and other healthcare providers involved in the treatment of patients with colorectal cancer. This CME Conference has been approved for a maximum of 1.0 AMA PRA Category 1 Credits.
Accrediation :
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.8 contact hours. Designated for 0.4 pharmacotherapy contact hours for Advance Practice Registered Nurses.
Course Description :
Colorectal cancer is the third most common cancer in men and women. Current evidence-based guidelines recommend that all metastatic colorectal tumors be tested for RAS mutations (both KRAS and NRAS) and BRAF mutations, as the presence of such mutations has implications for treatment. Clinical practice is variable, however, and many patients do not receive guideline-based care. This activity will examine optimal management of metastatic colorectal cancer.
Conference Objectives are :
Upon completion of this educational activity, the participant should be able to:
• Discuss the clinical relevance of extended RAS analysis at diagnosis and first relapse, BRAF testing, and MSI testing during workup for mCRC patients.
• Apply the most current evidence-based clinical practice guidelines to the management of patients with mCRC.
• Describe a multidisciplinary team approach to the management of mCRC involving surgery, radiation, and other treatment modalities.
• Review efficacy and safety data from clinical trials of approved agents being investigated for new indications in mCRC and for emerging investigational agents for the management of mCRC.
Additional details will be posted as soon as they are available.
SPECIALITIES
Oncology
Quick Links